PMID- 33663506
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210310
IS  - 1475-2867 (Print)
IS  - 1475-2867 (Electronic)
IS  - 1475-2867 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Mar 4
TI  - RNA sequencing reveals the expression profiles of circRNA and identifies a 
      four-circRNA signature acts as a prognostic marker in esophageal squamous cell 
      carcinoma.
PG  - 151
LID - 10.1186/s12935-021-01852-9 [doi]
LID - 151
AB  - BACKGROUND: CircRNAs with tissue-specific expression and stable structure may be 
      good tumor prognostic markers. However, the expression of circRNAs in esophageal 
      squamous cell carcinoma (ESCC) remain unknown. We aim to identify prognostic 
      circRNAs and construct a circRNA-related signature in ESCC. METHODS: RNA 
      sequencing was used to test the circRNA expression profiles of 73 paired ESCC 
      tumor and normal tissues after RNase R enrichment. Bioinformatics methods, such 
      as principal component analysis (PCA), t-distributed Stochastic Neighbor 
      Embedding (t-SNE) algorithm, unsupervised clustering and hierarchical clustering 
      were performed to analyze the circRNA expression characteristics. Univariate cox 
      regression analysis, random survival forests-variable hunting (RSFVH), 
      Kaplan-Meier analysis, multivariable Cox regression and ROC (receiver operating 
      characteristic) curve analysis were used to screen the prognostic circRNA 
      signature. Real-time quantitative PCR (qPCR) and fluorescence in situ 
      hybridization(FISH) in 125 ESCC tissues were performed. RESULTS: Compared with 
      normal tissues, there were 11651 differentially expressed circRNAs in cancer 
      tissues. A total of 1202 circRNAs associated with ESCC prognosis (P < 0.05) were 
      identified. Through bioinformatics analysis, we screened a circRNA signature 
      including four circRNAs (hsa_circ_0000005, hsa_circ_0007541, hsa_circ_0008199, 
      hsa_circ_0077536) which can classify the ESCC patients into two groups with 
      significantly different survival (log rank P < 0.001), and found its predictive 
      performance was better than that of the TNM stage(0.84 vs. 0.66; 0.65 vs. 0.62). 
      Through qPCR and FISH experiment, we validated the existence of the screened 
      circRNAs and the predictive power of the circRNA signature. CONCLUSION: The 
      prognostic four-circRNA signature could be a new prognostic biomarker for ESCC, 
      which has high clinical application value.
FAU - Wang, Weiwei
AU  - Wang W
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou University, Jian she Dong Road 1, Zhengzhou, 450052, Henan, China.
AD  - Department of Pathology, School of Basic Medicine, Zhengzhou University, 
      Zhengzhou, 450002, China.
AD  - Henan Key Laboratory for Tumor Pathology, Zhengzhou University, Zhengzhou, 
      450052, China.
FAU - Zhu, Di
AU  - Zhu D
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou University, Jian she Dong Road 1, Zhengzhou, 450052, Henan, China.
AD  - Department of Pathology, School of Basic Medicine, Zhengzhou University, 
      Zhengzhou, 450002, China.
AD  - Henan Key Laboratory for Tumor Pathology, Zhengzhou University, Zhengzhou, 
      450052, China.
FAU - Zhao, Zhihua
AU  - Zhao Z
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou University, Jian she Dong Road 1, Zhengzhou, 450052, Henan, China.
AD  - Department of Pathology, School of Basic Medicine, Zhengzhou University, 
      Zhengzhou, 450002, China.
AD  - Henan Key Laboratory for Tumor Pathology, Zhengzhou University, Zhengzhou, 
      450052, China.
FAU - Sun, Miaomiao
AU  - Sun M
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou University, Jian she Dong Road 1, Zhengzhou, 450052, Henan, China.
AD  - Department of Pathology, School of Basic Medicine, Zhengzhou University, 
      Zhengzhou, 450002, China.
AD  - Henan Key Laboratory for Tumor Pathology, Zhengzhou University, Zhengzhou, 
      450052, China.
FAU - Wang, Feng
AU  - Wang F
AD  - Department of Oncology, First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou University, Zhengzhou, 450052, China.
FAU - Li, Wencai
AU  - Li W
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou University, Jian she Dong Road 1, Zhengzhou, 450052, Henan, China.
AD  - Department of Pathology, School of Basic Medicine, Zhengzhou University, 
      Zhengzhou, 450002, China.
AD  - Henan Key Laboratory for Tumor Pathology, Zhengzhou University, Zhengzhou, 
      450052, China.
FAU - Zhang, Jianying
AU  - Zhang J
AD  - State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou 
      University, Zhengzhou, 450052, Henan, China. jianyingzhang@hotmail.com.
FAU - Jiang, Guozhong
AU  - Jiang G
AUID- ORCID: 0000-0001-6306-726X
AD  - Department of Pathology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou University, Jian she Dong Road 1, Zhengzhou, 450052, Henan, China. 
      guozhongjiang@zzu.edu.cn.
AD  - Department of Pathology, School of Basic Medicine, Zhengzhou University, 
      Zhengzhou, 450002, China. guozhongjiang@zzu.edu.cn.
AD  - Henan Key Laboratory for Tumor Pathology, Zhengzhou University, Zhengzhou, 
      450052, China. guozhongjiang@zzu.edu.cn.
LA  - eng
GR  - 81272371/National Natural Science Foundation of China/
GR  - 2018ZX10302205/National Major Science and Technology Projects of China/
GR  - 212102310134/Henan Programs for Science and Technology Development/
GR  - 18XTZX12007/Zhengzhou Major Project for Collaborative Innovation/
PT  - Journal Article
DEP - 20210304
PL  - England
TA  - Cancer Cell Int
JT  - Cancer cell international
JID - 101139795
PMC - PMC7934454
OTO - NOTNLM
OT  - Esophageal squamous cell carcinoma
OT  - Prognostic biomarker
OT  - Signature
OT  - Survival
OT  - circRNA
COIS- The authors declare no conflict of interest.
EDAT- 2021/03/06 06:00
MHDA- 2021/03/06 06:01
PMCR- 2021/03/04
CRDT- 2021/03/05 05:40
PHST- 2020/09/13 00:00 [received]
PHST- 2021/02/24 00:00 [accepted]
PHST- 2021/03/05 05:40 [entrez]
PHST- 2021/03/06 06:00 [pubmed]
PHST- 2021/03/06 06:01 [medline]
PHST- 2021/03/04 00:00 [pmc-release]
AID - 10.1186/s12935-021-01852-9 [pii]
AID - 1852 [pii]
AID - 10.1186/s12935-021-01852-9 [doi]
PST - epublish
SO  - Cancer Cell Int. 2021 Mar 4;21(1):151. doi: 10.1186/s12935-021-01852-9.